Regulation of heparin-binding epidermal growth factor-like growth factor mRNA levels by hypertrophic stimuli in neonatal and adult rat cardiac myocytes. 1994

M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a recently characterized member of the EGF family of peptide signaling factors that acts as an early response gene to growth stimuli in vascular smooth muscle cells, as well as being a potent mitogen for these cells. As many of these growth stimuli also induce a hypertrophic response in heart muscle, we examined the regulation of HB-EGF mRNA abundance and function in primary cultures of neonatal rat ventricular myocytes and adult rat ventricular myocytes (ARVM). HB-EGF mRNA levels increased 40- and 6-fold in neonatal rat ventricular myocytes and ARVM, respectively, following a 2-4-h exposure to the alpha-adrenergic agonist phenylephrine, a known hypertrophic stimulus for these cells. Phenylephrine had no effect on HB-EGF mRNA stability, and induction of HB-EGF could be blocked completely by actinomycin D. HB-EGF mRNA abundance was also increased 15-fold in ARVM maintained in defined medium that had been induced to contract at 3 Hz by continual uniform electric field stimulation, a mechanical stimulus that we have shown preserves contractile function and induces cell growth in vitro. To determine whether cardiac myocytes would respond to exogenous HB-EGF, quiescent ARVM were exposed to defined medium conditioned by transfected COS MT cells overexpressing HB-EGF. These myocytes exhibited nearly a 2-fold increase in protein content at 24 h compared with unstimulated control ARVM exposed to medium conditioned by COS cells transfected with the plasmid vector alone. Thus, neonatal and adult cardiac muscle cells respond to both neurohumoral and mechanical growth stimuli with a marked increase in HB-EGF mRNA, which may act as an early response gene to facilitate hypertrophic growth in these cells.

UI MeSH Term Description Entries
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D010812 Physical Stimulation Act of eliciting a response from a person or organism through physical contact. Stimulation, Physical,Physical Stimulations,Stimulations, Physical
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right

Related Publications

M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
August 1996, Neuroscience letters,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
May 1999, Brain research,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
August 1995, The Journal of clinical investigation,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
November 1993, Biochemical and biophysical research communications,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
September 1994, Kidney international,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
February 1998, Brain research,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
September 1994, Endocrinology,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
July 1994, Biochemical and biophysical research communications,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
January 2012, PloS one,
M A Perrella, and T Mäki, and S Prasad, and D Pimental, and K Singh, and N Takahashi, and M Yoshizumi, and A Alali, and S Higashiyama, and R A Kelly
December 1992, The Journal of biological chemistry,
Copied contents to your clipboard!